DCPH News and Press, Deciphera Pharmaceuticals Inc. From 11/03/22

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Deciphera Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation

Deciphera Pharmaceuticals press release ( NASDAQ: DCPH ): Q3 GAAP EPS of -$0.55 beats by $0.03 . Revenue of $35.97M (+54.9% Y/Y) beats by $2.96M . For further details see: Deciphera Pharmaceuticals GAAP EPS of -$0.55 beats by $0.03, revenue of $35.97M bea...

– Third Quarter 2022 Total Revenue of $36.0 Million; QINLOCK ® Net Product Revenue Increases 49% to $32.3 Million Compared to Third Quarter 2021 – – Presented Updated Results from Phase 1/2 Study of Vimseltinib in TGCT Patients at the ESMO Con...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its third quarter 2022 financial results on Thursda...

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this event. For further details see: Deciphera Pharmaceuticals (DCPH) Presents at ESMO Congress 2022

– Updated Results for Vimseltinib Showed Objective Response Rate of 69% in Phase 1, 53% in Phase 2 Cohort A, and 46% in Phase 2 Cohort B; Demonstrated a Clinical Benefit Rate of 100% Across All Phase 1/2 Patients – – Preliminary Patient-Reported Outcome Da...

– DCC-3116 Was Well-tolerated with No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events Observed – – Pharmacokinetic and Pharmacodynamic Data Across all Doses Levels Demonstrated Exposure and ULK 1/2 Inhibition Associated wit...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will host a virtual investor event to review clinical data from...

Deciphera Pharmaceuticals ( NASDAQ: DCPH ) has been initiated as a buy at Cowen based on growth in sales of its advanced gastrointestinal stromal tumor treatment Qinlock (ripretinib) and its pipeline. The firm has a $25 price target (~68% upside based on Friday's close). ...

Gainers: Microvast Holdings ( MVST ) +19% . Hydrofarm Holdings Group ( HYFM ) +7% . Mammoth Energy Services ( TUSK ) +5% . Twist Bioscience ( TWST ) +5% . Certara ( CERT ) +5% . Losers: Bed Bath & Beyond ( BBBY ) ...